Antibody | RA, +/76 | Control, +/41 | SN, % | SP, % | OR | 95% CI | p |
---|---|---|---|---|---|---|---|
Anti-CCP2 | 40/76 | 4/41 | 52.6 | 90.2 | 10.28 | 3.34–31.68 | < 0.01 |
RF-Neph | 27/76 | 1/41 | 35.5 | 97.6 | 22.04 | 2.87–169.36 | < 0.01 |
RF IgM | 32/76 | 5/41 | 42.1 | 87.8 | 5.24 | 1.85–14.82 | < 0.01 |
RF IgG | 8/76 | 2/41 | 10.5 | 95.1 | 2.29 | 0.46–11.35 | 0.31 |
RF IgA | 24/76 | 2/41 | 31.6 | 95.1 | 9.00 | 2.01–40.38 | < 0.01 |
≥ 1 RF* | 42/76 | 8/41 | 55.3 | 80.5 | 5.10 | 2.08–12.47 | < 0.01 |
≥ 2 RF* | 24/76 | 2/41 | 31.4 | 95.1 | 9.00 | 2.01–40.38 | < 0.01 |
Anti-CarP-FCS | 20/76 | 2/41 | 26.3 | 95.1 | 6.96 | 1.54–31.52 | 0.01 |
Anti-CarP-Fib | 12/76 | 2/41 | 15.8 | 95.1 | 3.66 | 0.78–17.21 | 0.10 |
Anti-CCP2 and/or ≥ 1 RF* | 51/76 | 11/41 | 67.1 | 73.2 | 5.56 | 2.40–12.89 | < 0.01 |
Anti-CCP2 and/or ≥ 1 RF* and/or anti-CarP-FCS | 52/76 | 13/41 | 68.4 | 68.3 | 4.68 | 2.06–10.56 | < 0.01 |
Anti-CCP2 and/or ≥ 2 RF* | 44/76 | 6/41 | 57.9 | 85.4 | 8.02 | 3.02–21.34 | < 0.01 |
Anti-CCP2 and/or ≥ 2 RF* and/or anti-CarP-FCS | 46/76 | 8/41 | 60.5 | 80.5 | 6.32 | 2.57–15.54 | < 0.01 |
RA cases sample n = 210, avg. samples/subject = 2.8; controls sample n = 136, avg. sample/subject = 3.3. OR, 95% CI, and p cannot be calculated because no controls met positivity criteria.
↵† Contains the following statistics: SN and SP.
↵* Count of RF by Neph and RF isotypes (IgM, IgG, IgA). RA: rheumatoid arthritis; RF: rheumatoid factor; Neph: nephelometry; anti-CCP2: anticyclic citrullinated peptide antibodies version 2; IgM: immunoglobulin M; anti-CarP: anti-carbamylated protein; FCS: fetal calf serum; Fib: fibrinogen; +/n: n positive over the case/control group size; SN: sensitivity; SP: specificity.